| Biomarker ID | 1204 |
| PMID | 23984644 |
| Year | 2013 |
| Biomarker | hsa-mir-31; hsa-mir-145; hsa-mir-455; hsa-mir-221; hsa-mir-222; hsa-mir-143; hsa-mir-221; hsa-mir-133b; hsa-mir-376c; hsa-mir-187; hsa-mir-139; hsa-mir-455; hsa-mir-224; hsa-mir-204; hsa-mir-505; hsa-mir-149; hsa-mir-222; hsa-mir-34a; hsa-mir-152; hsa-mir-30e; hsa-mir-377; hsa-mir-181c; |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa (log Fold Change): [] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Cancer Vs Benign |
| Type of Biomarker | Diagnostic |
| Cohort | The accession number of expression profile is GSE36802, containing 21 paired samples from prostate cancer tissue and benign prostate tissue. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p < 0.0401 |
| Method Used | Affymetrix miRNA Array |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | hsa-mir-31, hsa-mir-145, hsa-mir-455, hsa-mir-221, hsa-mir-222, hsa-mir-143, hsa-mir-221, hsa-mir-133b, hsa-mir-376c, hsa-mir-187, hsa-mir-139, hsa-mir-455, hsa-mir-224, hsa-mir-204, hsa-mir-505, hsa-mir-149, hsa-mir-222, hsa-mir-34a, hsa-mir-152, hsa-mir-30e, hsa-mir-377, hsa-mir-181c |